
    
      This is a Phase 2, , randomized (1:1), placebo-controlled, 2-weeks, proof-of-concept study to
      evaluate the safety and tolerability as well as the mechanistic effect of Aerosol
      administration of Inhaled All trans retinoic acid and oral Tamoxifen in subjects infected
      with COVID -19

      After randomization and standard treatment The infected patients will receive Aerosolized
      All-Trans Retinoic Acid in gradual in 2 divided doses increases from 0.2 mg/kg/day to 4
      mg/kg/day as inhaled All-Trans Retinoic Acid therapy plus tamoxifen 20mg orally once daily.
      for 14 days

      Inclusion Criteria:

      Adult SARI patients with 2019-ncov infection confirmed by PCR; Absolute value of lymphocytes
      < 0. 6x 109/L; Severe respiratory failure within 48 hours and requires admission to ICU.
      (severe respiratory failure was defined as PaO2/FiO2 < 200 mmHg and was supported by positive
      pressure mechanical ventilation (including non-invasive and invasive mechanical ventilation,
      PEEP>=5cmH2O))

      Exclusion Criteria:

      Age < 18 Pregnant Allergic to experimental drugs and patients have the following conditions:

      Hypercholesterolemia Hypertriglyceridemia Liver disease Renal disease SjÃ¶gren syndrome
      Pregnancy Lactation Depressive disorder Body mass index less than 18 points or higher than 25
      points Contraindications for hormonal contraception or intrauterine device. Autoimmune
      diseases A history of organ, bone marrow or hematopoietic stem cell transplantation Patients
      receiving anti-hcv treatment Permanent blindness in one eye History of iritis,
      endophthalmitis, scleral inflammation or retinitis 15-90 days of retinal detachment or eye
      surgery The competent physician considered it inappropriate to participate in the study
      Previous history of deep vein thrombosis or pulmonary embolism in the last 12 months.

      Patients with postmenopausal vaginal bleeding with no defined etiology. Patients with breast
      cancer who need to use tamoxifen for this neoplasm Another synchronous neoplasm that requires
      systemic treatment Patients with aggressive disease requiring cytotoxic therapy or
      locoregional therapies (eg hepatic embolization) A history of serious clinical or psychiatric
      illness that, by clinical judgment, may involve participation risk in this study Patients
      participating in other protocols with experimental drugs. Patients with oral food
      difficulties. Patients who underwent major recent surgery less than 4 weeks previously.
      Patients receiving chemotherapy or other oncologic therapy for less than 3 weeks

      Study Type: Interventional Primary Purpose: Treatment Study Phase: Phase 2 Interventional
      Study Model: Parallel Assignment Number of Arms: 2 Masking: None (Open Label) Allocation:
      Randomized Enrollment: 160 [Anticipated]
    
  